Lisa Sher

Lisa Sher has over a decade of experience in the investor relations and corporate development space. Lisa began their career in 2010 as Director of Business Development at OneMedPlace, where they managed investor relations and created capital partnerships for emerging life science companies. Lisa also organized bi-annual investor conferences such as OneMedForum in New York and San Francisco. In 2013, Lisa moved to MBS Value Partners as a Senior Investor Relations Associate, where they developed a life science vertical for an all senior level investor relations firm and was responsible for new business development. In 2014, Lisa joined the Biotechnology Innovation Organization as Director of Investor Relations and Programming, where they managed all investor related communication pertaining to BIO's initiatives and BIO's events. Lisa also led and directed investment community special events such as business development road shows, Nasdaq opening bell ceremony and KOL meetings/events. In 2016, Lisa moved to MBS Value Partners as a Senior Investor Relations Advisor. In 2017, they were appointed Head of Investor Relations at AC Immune. In 2019, Lisa joined Argot Partners as Senior Vice President and Opiant Pharmaceuticals as Senior Director of Investor Relations and Communications. In 2020, Lisa was appointed Managing Director at Stern Investor Relations. In 2021, they joined Tiberend Strategic Advisors, Inc. as SVP. Currently, Lisa is Head of Corporate Development at SteroTherapeutics.

Lisa Sher received a Bachelor of Arts degree from Boston University in International Relations, with a concentration in Economics.